LogicBio Therapeutics (LOGC) Misses Q2 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts LOGC Hot Sheet
Price: $7.06 --0%
EPS Growth %: +42.9%
Financial Fact:
Total operating expenses: 292.2K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +42.9%
Financial Fact:
Total operating expenses: 292.2K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
LogicBio Therapeutics (NASDAQ: LOGC) reported Q2 EPS of ($0.23).
For earnings history and earnings-related data on LogicBio Therapeutics (LOGC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tompkins Financial (TMP) Tops Q3 EPS by 5c
- Stephens Downgrades Illumina (ILMN) to Equal Weight
- Brunswick Corp (BC) PT Lowered to $66 at JPMorgan
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
